About: Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial
Creator	Dethlefsen, Uwe Fischer, Juergen
source	Medline; PMC
abstract	OBJECTIVE: Cineole has mucolytic, bronchodilating and anti-inflammatory properties and reduces the exacerbation rate in patients suffering from COPD, as well as ameliorates symptoms in patients suffering from asthma and rhinosinusitis. Based on these effects, we therefore postulated the hypothesis that patients with acute bronchitis would also benefit from therapy with Cineole. METHODS: As part of a double-blind, placebo-controlled, multi-center-study, a total of 242 patients with confirmed acute bronchitis was randomly selected to participate. Over a period of 10 days, all patients were administered 3 x 200 mg of Cineole, or a respective placebo, per day. The primary outcome measure was a Bronchitis Sum Score, which summarises the relevant symptoms of acute bronchitis. RESULTS: After 4 days of treatment it was notable, that the patient group treated with Cineole, showed significantly more improvements of the bronchitis-sum-score than those of the placebo group (p = 0.0383). The statistical significant difference of the individual outcome measures was especially underlined by the frequency of cough fits by p = 0.0001 after 4 days. CONCLUSIONS: The effects of Cineole in the treatment of acute bronchitis were clearly measurable and could be proven after a treatment period of merely 4 days. This study corroborates the fact that Cineole actively and significantly reduces cough frequency after four days. Therefore it has been shown to have a great socioeconomic impact. TRIAL REGISTRATION: ISRCTN: ISRCTN37784439
has issue date	2013-11-21(xsd:dateTime)
bibo:doi	10.1186/1745-9974-9-25
bibo:pmid	24261680
has license	cc-by
sha1sum (hex)	c7d8100f9f9f799f495a0458c8f23dcc7bcec3ec
schema:url	https://doi.org/10.1186/1745-9974-9-25
resource representing a document's title	Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial
has PubMed Central identifier	PMC3842692
has PubMed identifier	24261680
schema:publication	Cough
resource representing a document's body	covid:c7d8100f9f9f799f495a0458c8f23dcc7bcec3ec#body_text
is schema:about of	named entity 'reduces' named entity 'effects' named entity 'ASTHMA' named entity 'ACUTE BRONCHITIS' named entity 'EFFECTS' named entity 'AMELIORATES' named entity 'HYPOTHESIS' named entity 'RHINOSINUSITIS' named entity 'OBJECTIVE' named entity 'THERAPY' named entity 'MUCOLYTIC' named entity 'CINEOLE' named entity 'SUFFERING' named entity 'PROPERTIES' named entity 'CINEOLE' named entity 'COPD' named entity 'PLACEBO-CONTROLLED' named entity 'ACUTE BRONCHITIS' named entity 'DOUBLE-BLIND TRIAL' named entity 'EFFICACY' named entity 'ANTI-INFLAMMATORY' named entity 'BENEFIT' named entity 'RATE' named entity 'SUFFERING' named entity 'THESE' named entity 'EXACERBATION' named entity 'PATIENTS' named entity 'PATIENTS' named entity 'BASED' named entity 'SYMPTOMS' covid:arg/c7d8100f9f9f799f495a0458c8f23dcc7bcec3ec named entity 'suffering' named entity 'anti-inflammatory' named entity 'symptoms' named entity 'postulated' named entity 'cineole' named entity 'asthma' named entity 'rhinosinusitis' named entity 'acute bronchitis' named entity 'Cineole' named entity 'acute bronchitis' named entity 'cineole' named entity 'acute bronchitis' named entity 'Thoracic pain' named entity 'Cineole' named entity 'COPD' named entity 'Acute bronchitis' named entity 'pharmacological properties' named entity 'active ingredient' named entity 'primary outcome measure' named entity 'symptom' named entity 'double-blind, placebo-controlled' named entity 'symptom' named entity 'Cineole' named entity 'capsules' named entity 'treatment groups' named entity 'anti-inflammatory' named entity 'lung' named entity 'mucociliary clearance' named entity 'antibiotics' named entity 'statistically significant' named entity 'cough' named entity 'dyspnea' named entity 'ENT' named entity 'Bronchitis' named entity 'rales' named entity 'statistically significant' named entity 'Cineole' named entity 'inflammatory cells' named entity 'medical conditions' named entity 'Cineole' named entity 'anti-inflammatory' named entity 'follow-up' named entity 'symptom' named entity 'acute bronchitis' named entity 'therapeutic effects' named entity 'antibiotics' named entity 'acute bronchitis' named entity 'acute bronchitis' named entity 'parainfluenza virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software